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small, reflect the early stages and the patho-
genesis of fatal human cases.
Heike Aupperle, MD
Nicolas Doll, MD
Heart Center Leipzig
University of Leipzig
Leipzig, Germany
References
1. Aupperle H, Doll N, Walther T, Kornherr P,
Ullmann C, Schoon HA, et al. Ablation of
atrial fibriollation and esophageal injury: ef-
fects of energy source and ablation technique.
J Thorac Cardiovasc Surg. 2005;130:1549-54.
2. Aupperle H, Doll N, Walther T, Ullman C,
Schoon HA, Mohr FW. Histological findings
induced by different energy sources in atrial
ablation in sheep. Interactive Cardiovasc
Thorac Surg. 2005;4:450-5.
3. Doll N, Borger M, Fabricius A, Stephan S,
Gummert J, Hauss J, Kottkamp H, et al.
Esophageal perforation during left atrial radio-
frequency ablation: is the risk too high?
J Thorac Cardiovasc Surg. 2003;125:836-42.
4. Santiago T, Melo J, Gouveia RH, Martins
AP. Intra-atrial temperatures in radiofre-
quency endocardial ablation: histologic eval-
uation of lesions. Ann Thorac Surg. 2003;75:
1495-1501.
5. Santiago T, Melo J, Gouveia RH, Neves J.
Epicardial radiofrequency applications in
vitro and in vivo studies on human atrial
myocardium. Eur J Cardiothorac Surg. 2003;
24:481-6.
doi:10.1016/j.jtcvs.2006.03.063
Use of autologous adult stem cell for
treatment of congestive heart failure
To the Editor:
I read the article by Patel entitled “Surgical
treatment for congestive heart failure with
autologous adult stem cell transplantation: A
prospective randomized study” with great in-
terest.1-4 Clearly the authors have demon-
strated the effectiveness of injected autolo-
gous bone marrow stem cells to improve the
functional capacity of the failing heart.3-5 In
this clinical study they had the opportunity
to take biopsy specimens of myocardium at
the injection sites, but the nature of the cell
findings are not reported.
Did the biopsy specimens show the
CD34 marker?
Because no information is available in
regard to the presence of fibroblasts or scar
tissue, would it be possible that these tis-
sues are transforming through dedifferenti-
ation into myocardial tissue instead of stem
cell transformation? The implication of this
concept will allow investigators to concen-
trate more on the transduction signal path-
way rather than stem cells alone.
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Positron emission tomographic
scanning in the diagnosis and
staging of non–small cell lung
cancer 2 cm in size or less
To the Editor:
We read with interest the publication by
Port and colleagues.1 In fact, there is little
information in the literature on the role of
positron emission tomography (PET) in as-
sessing lung lesions of this size range for
malignancy, and well-defined studies are
needed. However, the current publication
has several shortcomings.
Most importantly, standard uptake value
(SUV) should not have been used to assess
the lung lesions for malignancy. SUV is a
semiquantitative measure of the tracer up-
take in the region of interest, which nor-
malizes the lesion activity to the injected
dose and body weight; SUV does not have
a unit. Despite initial enthusiasm, it is gen-
erally accepted that SUV should not be
used to differentiate malignant from benign
processes and that the visual interpretation
of PET studies by an experienced reader
provides the highest accuracy in diagnos-
ing malignancy.2-5 There are many factors
influencing the calculation of SUV, such as
the body weight and composition, the time
between tracer injection and image acqui-
sition, the spatial resolution of the PET
scanner, and the image reconstruction algo-
rithm. The clinical role of SUV in therapy
monitoring and as a measure of tumor ag-
gressiveness is currently under investigation.
Furthermore, the intensity of malignant
lesions on PET is influenced by the loca-
tion in the body. During PET acquisition,
which takes several minutes, lung lesions
move up and down, and their effective ac-
quisition time is reduced. Therefore the
fluorodeoxyglucose avidity of small lung
lesions is often underestimated. Conse-
quently, it is justified to use a “sensitive
reading” and consider tumors of mild in-
tensity to be malignant, although this likely
reduces the specificity. Additionally, the
non–attenuation-corrected (NAC) images
should be reviewed while dealing with
small lung lesions. Considering the mildly
intense appearance of small malignant lung
lesions on PET, it is reasonable to use the
NAC images and compare the tumor up-
take with the surrounding normal lung tis-
sue and not with the mediastinal blood pool
activity, as is the case while reading the
attenuation-corrected (AC) images. Although
large and markedly intense malignant foci
would likely be recognized on both NAC
and AC images, this might not be the case
for small foci. Also, the pathophysiologic
basis of fluorodeoxyglucose PET rests on
increased expression of Glut, upregulation
of hexokinase activity, and downregulation
of glucose-6-phosphatase activity in the
cancer cells compared with the normal cells
of the same organ, the lung in this case.
In our experience PET can be very help-
ful in detecting malignancy in lung lesions
measuring 6 to 10 mm, provided the im-
ages are read with attention to the issues
mentioned (NAC images, sensitive read-
ing, and avoidance of SUV thresholds).
Sensitivity and specificity of PET for de-
tecting malignancy in small lung lesions
(6-10 mm) is currently being evaluated by
us in an ongoing prospective study.
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Reply to the Editor:
We thank Drs Khandani and Detterbeck for
their insightful comments on our article. Its
main conclusion was that standard uptake
values (SUVs) obtained from positron emis-
sion tomographic (PET) imaging were not
useful for staging lung cancers smaller than
2 cm. We note that there was no disagree-
ment with that conclusion, but rather the
suggestion that visual inspection by experi-
enced readers is now the accepted standard.
A listing of some of the technical reasons
why SUVs can be misleading is then given.
We agree that several recent articles
have suggested that an expert reading may
be equivalent to or better than a single cutoff
for SUV. However, this is by no means a
generally accepted standard. In fact, clini-
cians overwhelmingly continue to use the
maximum SUV for differentiating benign
from malignant lesions. This clinical prac-
tice is influenced by early PET reports,1 in
which a remarkably high accuracy of SUV
was reported for differentiating benign
from malignant nodules.
The problems outlined by Drs Khandani
and Detterbeck regarding the limitations of
the maximum SUV also affect the capabil-
ity of experienced clinicians in making
evaluations. Ultimately, anything that lim-
its the ability to make quantitative assess-
ments will also affect semiquantitative or
nonquantitative assessments as well. The
latest efforts in PET imaging include add-
ing some form of gating to improve quan-
titative assessments, and likely there will
again be discussion of whether this will
become the new accepted standard. For
now, the maximum SUV continues to be
reported and to guide clinical practice. We
look forward to improvements in PET tech-
nology and remain hopeful that the utility
of PET for small lesions will improve;
however, there are some fundamental lim-
itations that we believe will continue to be
problematic in the foreseeable future.
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Pulmonary lobectomy for cancer in
patients with chronic obstructive
pulmonary disease
To the Editor:
We have read with interest the report from
Baldi and colleagues1 reporting their expe-
rience with pulmonary lobectomy for lung
cancer in patients with chronic obstructive
pulmonary disease (COPD).1 On the basis
of their retrospective evaluation of 137 pa-
tients, they concluded that patients with
mild-to-severe COPD could have a better
late preservation of pulmonary function af-
ter lobectomy than healthy patients. As dis-
cussed in a very precise way by the authors,
this fact is related to a general improve-
ment of the airway caliber and elastic recoil
that could be, in its turn, related to relief of
hyperinflation, chest wall mechanics, or
both, even if in the nonemphysematous
lung. In addition, resection of dead space
could have its role.
We would like to briefly comment on
these figures, trying to relate them to the
possible role a pulmonary rehabilitation
(PR) program might have in this kind of
surgical population, and kindly ask for the
authors to disclose their point of view ac-
cording to their experience.
Today there is body of evidence regard-
ing the efficacy of PR in the comprehensive
management of patients with respiratory
disease, and PR programs are practiced
worldwide.2 Positive results in terms of
improvement in dyspnea, exercise capac-
ity, and quality of life are recognized in
chronic obstructive and nonobstructive pul-
monary disease, including COPD, cystic
fibrosis, and restrictive thoracic disease.3,4
Our group has a timely established in-
terest in the issue of PR applied to patients
who have undergone (or are candidates for)
resection for lung cancer, and we have re-
ported evidence that patients who under-
went PR after pulmonary resection demon-
strated a better improvement than those
who, at discharge from the surgical unit,
did not attend any postoperative rehabilita-
tion protocol. In fact, we have reported that
an early postoperative rehabilitative inter-
vention prevents deterioration and speeds
up recovery of function, with direct effects
on ventilatory, gas exchange, and hemody-
namic parameters (work of breathing, lung
compliance, alveolar-arterial difference,
maximum oxygen consumption, arterial
oxygen tension, heart rate, arterial lactate
concentration, cardiac index, and pulmo-
nary artery pressure) and little or no signif-
icant effect on static and dynamic lung
volumes, according to previously outlined
experiences.5 Further analysis (data sub-
mitted for publication) of our experience
supports this evidence. Because it appears
that only patients with mild-to-severe
COPD obtain an improvement in terms of
lung volumes (related to the preoperative
COPD index also)1 from the removal of
lung parenchyma associated with resection
for cancer, we would like the authors to
comment on the fact that a postoperative
rehabilitation program adopted in these pa-
tients could improve ventilatory, hemody-
namic, and gas exchange parameters con-
curring to a better clinical outcome and
quality of life status.
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